Chiasma

OverviewSuggest Edit

Chiasma applies its proprietary technology to approved drugs, which not only enables their being switched from injectable to oral, but importantly can result in new indications and/or enhanced absorption. The Company's Transient Permeability Enhancer technology promotes the delivery of drugs to the GI wall and from there to the liver. It is applicable to macromolecules that to-date can be administered only by injection. TPE can be utilized also with small molecules that are already orally available but are poorly absorbed.
TypePublic
Founded2001
HQNeedham, USMap
Websitechiasmapharma.com
Employee Ratings4.5More
View Jobs

Recent NewsAll News

Latest Updates

Employees (est.) (Mar 2020)48(+167%)
Share Price (Oct 2020)$3.9
Cybersecurity ratingBMore

Key People/Management at Chiasma

Roni Mamluk

Roni Mamluk

CEO
Dana Gelbaum

Dana Gelbaum

VP of BD and Supply Chain
Shoshie Katz

Shoshie Katz

VP of Quality Assurance & Regulatory Affairs
Asi Haviv

Asi Haviv

VP of Clinical Development
Lillian Kuan

Lillian Kuan

Alumni Advisory Committee Board Member
Show more

Chiasma Office Locations

Chiasma has offices in Needham, Waltham and Ness Ziona
Needham, US (HQ)
140 Kendrick St Building C
Waltham, US
460 Totten Pond Rd #530
Ness Ziona, IL
5 Golda Me'ir St
Show all (3)

Chiasma Financials and Metrics

Chiasma Revenue

USD

Net income (Q2, 2020)

(21.1m)

EBIT (Q2, 2020)

(20.3m)

Market capitalization (23-Oct-2020)

224.3m

Closing stock price (23-Oct-2020)

3.9

Cash (30-Jun-2020)

52.2m
Chiasma's current market capitalization is $224.3 m.
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

General and administrative expense

16.5m21.8m9.1m10.0m15.1m

R&D expense

19.0m31.3m17.9m22.4m22.5m

Operating expense total

35.4m61.3m28.1m32.3m37.6m

EBIT

(35.4m)(61.3m)(28.1m)(32.3m)(37.6m)
Quarterly
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

General and administrative expense

3.4m4.8m10.0m5.4m3.9m2.5m2.6m2.3m2.4m2.6m2.3m2.5m2.6m4.1m7.6m10.7m

R&D expense

4.2m4.4m7.2m14.8m4.5m4.7m4.3m4.7m4.9m6.3m5.5m6.5m5.5m4.1m8.1m9.7m

Operating expense total

7.6m9.2m17.2m26.7m9.4m7.1m6.9m6.9m7.3m8.9m7.7m8.9m8.2m8.2m15.7m20.3m

EBIT

(7.6m)(9.2m)(17.2m)(26.7m)(9.4m)(7.1m)(6.9m)(6.9m)(7.3m)(8.9m)(7.7m)(8.9m)(8.2m)(8.2m)(15.7m)(20.3m)
show all
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

41.0m37.0m14.6m13.1m27.9m

Prepaid Expenses

1.8m2.2m3.9m

Inventories

2.3m2.1m

Current Assets

151.1m95.1m68.7m62.2m96.3m
Quarterly
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

63.3m140.9m39.1m30.5m28.5m19.0m18.4m12.1m15.2m13.8m11.2m10.1m20.6m19.7m42.6m52.2m

Prepaid Expenses

466.0k1.4m3.8m2.5m2.2m1.8m1.4m2.2m1.7m1.2m1.7m1.4m1.1m3.0m4.9m3.7m

Current Assets

63.7m164.2m138.1m118.1m101.6m86.8m81.5m75.3m62.2m55.8m49.8m53.5m59.3m105.7m84.1m70.8m

PP&E

570.6k573.5k1.7m2.6m2.4m646.0k607.0k584.0k175.0k153.0k130.0k102.0k96.0k209.0k590.0k617.0k
show all
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(35.9m)(61.1m)(26.8m)(31.3m)(36.3m)

Depreciation and Amortization

201.0k433.0k152.0k88.0k55.0k

Inventories

(1.7m)674.0k

Accounts Payable

(161.0k)1.8m(1.6m)4.3m111.0k
Quarterly
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Net Income

(12.0m)(21.4m)(17.2m)(43.8m)(53.2m)(7.0m)(13.9m)(20.7m)(7.0m)(15.7m)(23.2m)(8.7m)(16.6m)(24.3m)(15.4m)(36.5m)

Depreciation and Amortization

98.6k146.2k59.0k153.0k373.0k40.0k79.0k119.0k23.0k46.0k69.0k16.0k29.0k42.0k26.0k73.0k

Accounts Payable

358.5k366.0k(457.0k)(670.0k)(613.0k)1.7m3.1m3.2m(751.0k)(1.2m)(1.9m)2.9m5.8m

Cash From Operating Activities

(11.9m)(19.9m)(12.8m)(29.7m)(45.6m)(6.3m)(11.3m)(18.2m)(4.8m)(10.8m)(17.5m)(7.9m)(16.1m)(25.3m)(12.6m)(29.0m)
show all
USDQ2, 2015

Financial Leverage

-0.8 x
Show all financial metrics

Chiasma Cybersecurity Score

Cybersecurity ratingPremium dataset

B

81/100

Learn more about about our premium products
SecurityScorecard logo

Chiasma Online and Social Media Presence

Chiasma's Trends

Embed Graph

Chiasma News and Updates

October 01, 2020

Chiasma Announces Planned Transition of Former CEO

Mark Fitzpatrick to Step Down as President and Principal Financial Officer Following the Appointment of a New Chief Financial Officer Mark Fitzpatrick to Step Down as President and Principal Financial Officer Following the Appointment of a New Chief Financial Officer
June 05, 2019

Chiasma Strengthens Leadership Team Ahead of Anticipated Commercial Availability of Mycapssa®

Appoints pharma commercial veteran Raj Kannan as Chief Executive Officer
March 29, 2019

Chiasma Announces Pricing of Underwritten Public Offering of $30.0 Million of Common Stock

WALTHAM, Mass., March 29, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (Nasdaq: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today announced the pricing of an underwritten public offering of 6,315,790 shares of its c…
March 08, 2019

Chiasma Reports Fourth Quarter and Year End 2018 Results

On track for top-line data from Phase 3 CHIASMA OPTIMAL trial of octreotide capsules, conditionally trade-named MYCAPSSA®, expected in Q3 2019
October 01, 2018

Chiasma Completes Enrollment of CHIASMA OPTIMAL Phase 3 Clinical Trial of Octreotide Capsules in Patients with Acromegaly

September 13, 2018

Chiasma Announces Poster Presentation at the 9th International Congress of the Growth Hormone Research and IGF Societies

Among the initial findings, some acromegaly patients managed by injectable somatostatin receptor ligands (SRLs) report symptoms that may interfere with daily life
Show more

Chiasma Blogs

November 14, 2019

Chiasma to Present at the 13th Acromegaly Consensus Conference

Company on-track to submit MYCAPSSA® NDA by year-end 2019 WALTHAM, Mass. , Nov. 14, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today announced that William
November 05, 2019

Chiasma Reports Third Quarter 2019 Results

CHIASMA OPTIMAL trial, conducted under SPA and designed to support FDA approval, met the primary and all secondary endpoints MYCAPSSA ® NDA on track for submission by year-end 2019 MPOWERED TM Phase 3 trial, designed to support EU approval, progressing as planned with topline data expected in 2H
November 01, 2019

Chiasma Supports Acromegaly Awareness Day

WALTHAM, Mass. , Nov. 01, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today recognizes November 1 st as Acromegaly Awareness Day.    “We recognize Acromegaly
October 29, 2019

Chiasma to Report Third Quarter Financial Results on November 5, 2019

Company to host conference call and webcast at 5:00pm ET WALTHAM, Mass. , Oct. 29, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (Nasdaq: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today announced that it will host a
September 25, 2019

Chiasma to Present at the Cantor 2019 Global Healthcare Conference

WALTHAM, Mass. , Sept. 25, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today announced that Raj Kannan, Chief Executive Officer and Dr.
August 08, 2019

Chiasma Reports Second Quarter 2019 Results

Chiasma Reports Second Quarter 2019 Results Content Import Thu, 08/08/2019 - 16:05 Chiasma Reports Second Quarter 2019 Results August 8, 2019 at 4:05 PM EDT This release is a backfill from a News Wire Earnings Announces positive data …
Show more

 Chiasma Frequently Asked Questions

  • When was Chiasma founded?

    Chiasma was founded in 2001.

  • Who are Chiasma key executives?

    Chiasma's key executives are Roni Mamluk, Dana Gelbaum and Shoshie Katz.

  • How many employees does Chiasma have?

    Chiasma has 48 employees.

  • Who are Chiasma competitors?

    Competitors of Chiasma include Principia BioPharma, Ginkgo Bioworks and Verona Pharma.

  • Where is Chiasma headquarters?

    Chiasma headquarters is located at 140 Kendrick St Building C, Needham.

  • Where are Chiasma offices?

    Chiasma has offices in Needham, Waltham and Ness Ziona.

  • How many offices does Chiasma have?

    Chiasma has 3 offices.